Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Generalized osteosclerosis with periosteal bone formation, characteristic facial dysmorphism, brain abnormalities including intracerebral calcifications, and neonatal lethal course.
Features include always present findings: Subperiosteal bone formation and Increased bone density (increased bone mineral density); and very common findings: Thoracic hypoplasia. 50 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 4 | Hydrocephalus, Global developmental delay, Cerebral calcification |
FAM20C encodes FAM20C golgi associated secretory pathway kinase (584 aa). Golgi serine/threonine protein kinase that phosphorylates secretory pathway proteins within Ser-x-Glu/pSer motifs and plays a key role in biomineralization of bones and teeth.
Lethal osteosclerotic bone dysplasia is strongly associated with mutations in the FAM20C gene on chromosome 7.
The FAM20C protein participates in FAM20C substrates and FAM20C:FAM20C substrates pathways.
FAM20C is classified as a druggable target (Druggable Genome, Enzyme, Kinase, and Serine Threonine Kinase categories) with score 0.0.
Genetic testing for FAM20C is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 2 always present features, 1 very common feature, 2 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for lethal osteosclerotic bone dysplasia.
5 publications have been identified in PubMed for lethal osteosclerotic bone dysplasia. Research spans Review / Meta-Analysis (40%), Basic Science / Preclinical (40%), and Case Report / Case Series (20%).
Au CW (2026). [PMID: 41174912](https://pubmed.ncbi.nlm.nih.gov/41174912/). *Am J Med Genet A*. [Case Report / Case Series]
Lazarczyk E (2026). [PMID: 41896969](https://pubmed.ncbi.nlm.nih.gov/41896969/). *Orphanet J Rare Dis*. [Review / Meta-Analysis]
Chen M (2025). [PMID: 39748245](https://pubmed.ncbi.nlm.nih.gov/39748245/). *BMC Mol Cell Biol*. [Basic Science / Preclinical]
Toraman B (2025). [PMID: 40794899](https://pubmed.ncbi.nlm.nih.gov/40794899/). *Hum Mol Genet*. [Basic Science / Preclinical]
Baker A (2025). [PMID: 41241263](https://pubmed.ncbi.nlm.nih.gov/41241263/). *Matrix Biol*. [Review / Meta-Analysis]
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 11:55 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Head and neck
4 |
Cleft palate, Microcephaly, High palate |
Bones and joints | 3 | Subperiosteal bone formation, Increased bone density (increased bone mineral density), Bowing of the long bones |
Growth and development | 1 | Short stature |
Lab test results | 1 | Elevated circulating alkaline phosphatase concentration |
Lungs and breathing | 1 | Pulmonary hypoplasia |
Ears | 1 | Mixed hearing impairment |
Muscles | 1 | Joint stiffness present at birth (arthrogryposis multiplex congenita) |